Alphatec Spine Receives U.S. FDA 510(K) Market Clearance for Two New Products and Receives Japanese Shonin Approval to Begin

Alphatec Spine Receives U.S. FDA 510(K) Market Clearance for Two New Products
and Receives Japanese Shonin Approval to Begin Marketing Its Novel(R) Peek
Lumbar Spinal Spacers

CARLSBAD, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc.
(Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device
company that designs, develops, manufactures and markets products for the
surgical treatment of spine disorders, with a focus on treating conditions
related to the aging spine, today provided an update related to its product
commercialization efforts.

The Company announced that it has recently received 510(k) market clearance
from the U.S. Food and Drug Administration (FDA) for two new products in the
Company's new product pipeline:

  *An anchored, anterior cervical interbody device, called Pegasus™, which
    offers single-step deployment of the anchoring blades without the need for
    impaction; and,
  *A new MIS system, called ILLICO® FS Facet Fixation System, which enables
    spine surgeons to immobilize and stabilize spinal segments without the
    need for pedicle screw and rod constructs.

Additionally, the Company said that it has received Shonin approval in Japan
from the Pharmaceuticals and Medical Devices Agency to market and sell three
lines of the Company's Novel PEEK Spinal Spacers, including the Novel SD, the
Novel LCC and the Novel TL, which are used in posterior spine fusion
procedures. PEEK, or polyetheretherketone, is a radiolucent material
containing radiographic markers, which enhance interbody visualization and
alignment during the fusion process.

"I am pleased to announce these important new developments related to our new
product commercialization strategy at Alphatec Spine," said Les Cross,
Chairman and CEO of Alphatec Spine. Our initiatives to strengthen the top-line
growth of the Company through robust internal product development,
acquisitions and license arrangements, and continued global expansion are
gaining momentum. Our new Pegasus anchored cervical interbody device and
ILLICO FS system represent key additions to our cervical and MIS offerings in
the U.S., respectively.

"In Japan, product registration has been a long and complex process and we are
pleased to have achieved that significant milestone for our Novel PEEK Spinal
Spacer Systems, complementing the strong sales presence we have already
established there."

About Alphatec Spine

Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc.
(Nasdaq:ATEC). Alphatec Spine is a medical device company that designs,
develops, manufactures and markets products for the surgical treatment of
spine disorders, primarily focused on the aging spine. The Company's mission
is to combine world-class customer service with innovative, surgeon-driven
products that will help improve the aging patient's quality of life.The
Company is poised to achieve its goal through new solutions for patients with
osteoporosis, stenosis and other aging spine deformities, improved minimally
invasive products and techniques and integrated biologics solutions.In
addition to its U.S. operations, the Company also markets its products in over
50 international markets through its affiliate, Scient'x S.A.S., via a direct
sales force in France, Italy and the United Kingdom and via independent
distributors in the rest of Europe, the Middle East and Africa. In Latin
America, the Company conducts its business through its subsidiary, Cibramed
Produtos Medicos.In Japan, the Company markets its products through its
subsidiary, Alphatec Pacific, Inc.In the rest of Asia and Australia, the
Company sells its and Scient'x's products through its and Scient'x's

The Alphatec Holdings, Inc. logo is available at

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainty. Such statements are based on management's current expectations
and are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no assurance
that actual results or business conditions will not differ materially from
those projected or suggested in such forward-looking statements as a result of
various factors. Forward-looking statements include references to the
Company's ability to develop and commercialize new products targeted for U.S.
and international markets.The words "believe," "will," "should," "expect,"
"intend," "estimate" and "anticipate," variations of such words and similar
expressions identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. The important
factors that could cause actual operating results to differ significantly from
those expressed or implied by such forward-looking statements include, but are
not limited to; the uncertainty of success in developing new products or
products currently in Alphatec Spine's pipeline; the uncertainty of success in
acquiring new products or technologies; the successful launch of the Company's
new products and the products in its development pipeline, including the
products discussed in this press release; failure to achieve acceptance of
Alphatec Spine's products by the surgeon community, including the products
discussed in this press release; failure to successfully implement
streamlining activities to create operating cost savings; failure to
successfully begin in-house manufacturing of certain products; failure to
obtain or maintain regulatory clearance or approval for products, including
the products discussed in this press release, or unexpected or prolonged
delays in the process; Alphatec Spine's ability to develop and expand its U.S.
and/or global revenues; continuation of favorable third party payor
reimbursement for procedures performed using Alphatec Spine's products;
unanticipated expenses or liabilities or other adverse events affecting cash
flow or Alphatec Spine's ability to successfully control its costs or achieve
profitability; uncertainty of additional funding; Alphatec Spine's ability to
compete with other competing products and with emerging new technologies;
product liability exposure; failure to meet all financial obligations in the
Cross Medical Settlement; patent infringement claims and claims related to
Alphatec Spine's intellectual property. Please refer to the risks detailed
from time to time in Alphatec Spine's SEC reports, including its Annual Report
Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form
8-K. Alphatec Spine disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact:
         Mark Francois
         Senior Director, Investor Relations
         Alphatec Spine, Inc.
         (760) 494-6610

Alphatec Spine
Press spacebar to pause and continue. Press esc to stop.